Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Recent Update on Development of Small-Molecule STAT3 Inhibitors for Cancer Therapy: From Phosphorylation Inhibition to Protein Degradation
Jinyun Dong, Xiangdong Cheng, Weidong Zhang, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 13, pp. 8884-8915
Closed Access | Times Cited: 132

Showing 26-50 of 132 citing articles:

Unveiling the potential of isatin-grafted phenyl-1,2,3-triazole derivatives as dual VEGFR-2/STAT-3 inhibitors: Design, synthesis and biological assessments
Heba A. Elsebaie, Maha-Hamadien Abdulla, Zainab M. Elsayed, et al.
Bioorganic Chemistry (2024) Vol. 151, pp. 107626-107626
Closed Access | Times Cited: 5
The role of the STAT3 signaling transduction pathways in radioresistance
Po‐Chang Shih
Pharmacology & Therapeutics (2022) Vol. 234, pp. 108118-108118
Closed Access | Times Cited: 21
Identification of marine natural product Pretrichodermamide B as a STAT3 inhibitor for efficient anticancer therapy
Rui Li, Yue Zhou, Xinxin Zhang, et al.
Marine Life Science & Technology (2023) Vol. 5, Iss. 1, pp. 94-101
Open Access | Times Cited: 12
Endothelial Stat3 activation promotes osteoarthritis development
LI Yon, Wen-Cai Zhang, Xinru Liu, et al.
Cell Proliferation (2023) Vol. 56, Iss. 12
Open Access | Times Cited: 12
Small Molecules as Anti‐inflammatory Agents: Molecular Mechanisms and Heterocycles as Inhibitors of Signaling Pathways
N. Jeelan Basha
ChemistrySelect (2023) Vol. 8, Iss. 9
Closed Access | Times Cited: 11
Emerging Pharmacotherapeutic Strategies to Overcome Undruggable Proteins in Cancer
Yuqing Lu, Yuewen Yang, Guanghao Zhu, et al.
International Journal of Biological Sciences (2023) Vol. 19, Iss. 11, pp. 3360-3382
Open Access | Times Cited: 11
Toosendanin induces hepatotoxicity by restraining autophagy and lysosomal function through inhibiting STAT3/CTSC axis
Li Luo, Jiajie Ni, Jiahui Zhang, et al.
Toxicology Letters (2024) Vol. 394, pp. 102-113
Closed Access | Times Cited: 3
Dual-Targeted Self-Adjuvant Heterocyclic Lipidoid@Polyester Hybrid Nanovaccines for Boosting Cancer Immunotherapy
Zixu Liu, Boyuan Liu, Yu-Peng Feng, et al.
ACS Nano (2024) Vol. 18, Iss. 24, pp. 15557-15575
Closed Access | Times Cited: 3
Structural Optimization of Marine Natural Product Pretrichodermamide B for the Treatment of Colon Cancer by Targeting the JAK/STAT3 Signaling Pathway
Yue Zhou, Na He, Qian Liu, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 13, pp. 10783-10794
Closed Access | Times Cited: 3
SNORA28 Promotes Proliferation and Radioresistance in Colorectal Cancer Cells through the STAT3 Pathway by Increasing H3K9 Acetylation in the LIFR Promoter
Xin Liu, Hong Zhang, Ying Fan, et al.
Advanced Science (2024) Vol. 11, Iss. 32
Open Access | Times Cited: 3
Targeting the STAT3 pathway with STAT3 degraders
Zhijie Wang, Xiaotong Liao, Haiqi He, et al.
Trends in Pharmacological Sciences (2024) Vol. 45, Iss. 9, pp. 811-823
Closed Access | Times Cited: 3
DDIAS, DNA damage-induced apoptosis suppressor, is a potential therapeutic target in cancer
Joo‐Young Im, Mi‐Jung Kang, Bo‐Kyung Kim, et al.
Experimental & Molecular Medicine (2023) Vol. 55, Iss. 5, pp. 879-885
Open Access | Times Cited: 10
Research progress of STAT3-based dual inhibitors for cancer therapy
Xiao-Juan Yang, Lu Xu, Yang Li, et al.
Bioorganic & Medicinal Chemistry (2023) Vol. 91, pp. 117382-117382
Closed Access | Times Cited: 10
A Network Pharmacology Prediction and Molecular Docking-Based Strategy to Explore the Potential Pharmacological Mechanism of Astragalus membranaceus for Glioma
Yu Feng, Peng Zhu, Dong Wu, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 22, pp. 16306-16306
Open Access | Times Cited: 9
Blockade of STAT3/IL-4 overcomes EGFR T790M-cis-L792F-induced resistance to osimertinib via suppressing M2 macrophages polarization
Yiting Sun, Yiting Dong, Xijuan Liu, et al.
EBioMedicine (2022) Vol. 83, pp. 104200-104200
Open Access | Times Cited: 17
The STAT family: Key transcription factors mediating crosstalk between cancer stem cells and tumor immune microenvironment
Mengxuan Zhu, Suyao Li, Xin Cao, et al.
Seminars in Cancer Biology (2022) Vol. 88, pp. 18-31
Closed Access | Times Cited: 17
Discovery of benzochalcone derivative as a potential antigastric cancer agent targeting signal transducer and activator of transcription 3 (STAT3)
Jinyun Dong, Jing Yang, Wen-Kai Yu, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2022) Vol. 37, Iss. 1, pp. 2004-2016
Open Access | Times Cited: 15
Tumor-associated macrophages mediate resistance of EGFR-TKIs in non-small cell lung cancer: mechanisms and prospects
Daoan Cheng, Kele Ge, Xue Yao, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 8
Synthesis and evaluation of WK-X-34 derivatives as P-glycoprotein (P-gp/ABCB1) inhibitors for reversing multidrug resistance
Fei Cao, Yulong Li, Furong Ma, et al.
RSC Medicinal Chemistry (2023) Vol. 15, Iss. 2, pp. 506-518
Closed Access | Times Cited: 8
Synthesis of 1,3,4-Thiadiazole Derivatives and Their Anticancer Evaluation
Camelia Elena Stecoza, George Mihai Niţulescu, Constantin Drǎghici, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 24, pp. 17476-17476
Open Access | Times Cited: 8
Design, synthesis and biological evaluation of novel naphthoquinothiazole derivatives as potent antitumor agents through inhibiting STAT3
Dongmei Fan, Pingxian Liu, Z.-Q. Li, et al.
Bioorganic Chemistry (2024) Vol. 150, pp. 107565-107565
Closed Access | Times Cited: 2
Prioritizing drug targets by perturbing biological network response functions
Matthew C. Perrone, Michael G. Lerner, Matthew Dunworth, et al.
PLoS Computational Biology (2024) Vol. 20, Iss. 6, pp. e1012195-e1012195
Open Access | Times Cited: 2
Research progress of multi-target HDAC inhibitors blocking the BRD4-LIFR-JAK1-STAT3 signaling pathway in the treatment of cancer
Shuting Jia, Yuye Jia, Sufang Liang, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 110, pp. 117827-117827
Closed Access | Times Cited: 2
Bipyridine Derivatives as NOP2/Sun RNA Methyltransferase 3 Inhibitors for the Treatment of Colorectal Cancer
Zhen Tang, Ningjing Zhang, Shuang Chen, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 15, pp. 13446-13473
Closed Access | Times Cited: 2
Structure, function, signaling pathways and clinical therapeutics: The translational potential of STAT3 as a target for cancer therapy
Dandan Shi, Jiejing Tao, Shuli Man, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 6, pp. 189207-189207
Closed Access | Times Cited: 2

Scroll to top